Roche says its planned purchase of cancer data specialist Flatiron Health Inc. will help the Swiss group progress its own pipeline while helping to design the use of real-world evidence (RWE) to set new industry standards for oncology research and development.
The acquisition, announced Feb. 15, stems from an existing partnership between the two companies,with Roche already holding a 12.6% stake in Flatiron. Roche said it will pay $1
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?